| 查看: 1911 | 回复: 5 | |||
[交流]
【讨论】非索非那定的市场情况
|
|
求：非索非那定的 一、产品研发背景 1. 原研厂家 2. 研发时间与研究立意 3.国外的上市与销售情况 二、与现有竞争产品的比较 三、国内市场情况 1.批文数量及厂家（含规格） 2. 历史销售情况及分析 3.国内主要生产厂家的销售情况 |
回复此楼» 猜你喜欢
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有0人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有2人回复
-
药物学论文润色/翻译怎么收费?
已经有179人回复
-
26申博自荐
已经有12人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
医药研发数据库资源
已经有4人回复
-
求大佬收留
已经有0人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 现在国内有那几家在生产毒莠定？市场情况如何？
已经有4人回复
» 抢金币啦！回帖就可以得到:
-
告别流水线爽文！108万字完结仙侠《女娲石之灵石奇缘（仙界篇）》值得细品
+1/5787
-
基金申请小调查！祝申请必定中！！祈福！！！
+5/315
-
基金祈福
+1/159
-
散金币
+1/126
-
上海交通大学张航课题组招聘博士后（电化学储能）
+1/87
-
青基的材料青椒们，可以把硕士联培生送我这里，要研二男生
+2/62
-
武汉，诚征男友，不异地，年龄大了
+1/36
-
清华大学环境课题组招聘环境工作专业客座生研究生2-3名（应用导向）
+1/22
-
清华大学环境课题组招聘环境工作专业客座生研究生2-3名（应用导向）
+1/21
-
这些国际期刊正在招募青年编委
+1/13
-
安徽医科大学周可成教授课题组诚聘博士后 2026年
+1/12
-
安徽医科大学周可成教授课题组诚聘博士后 2026年
+1/10
-
【招聘专职科研、专职工程人员】上海交通大学桐乡高等研究院招聘启事(本招聘长期有效)
+1/9
-
南方医科大学深圳医院陈烨/余涛教授课题组联合培养博士后招聘
+1/4
-
中科院大连化学物理研究所 招聘 催化剂研发方向 科研助理 2名
+1/4
-
南京大学 智能驱动与感知材料实验室 诚招申请考核博士生/科研助理/博士后
+1/4
-
祈祷老公中国基
+1/3
-
出全新蔡司 Plan?APOCHROMAT 20×/0.8 平场复消色差物镜
+1/2
-
新审查指南施行半年，AI方向的专利申请是不是更看"技术味"了？
+1/2
-
【产品测评分享】体外转录产量不理想、dsRNA 副产物高？T7 RNA 聚合酶实测体验
+1/1
2楼2011-03-18 12:51:27
★ ★ ★
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
|
Fexofenadine hydrochloride Cas number: 153439-40-8, 138452-21-8 - General description: Fexofenadine (trade names Allegra, Telfast, Fastofen, Tilfur, Vifas, Telfexo, Allerfexo) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine (trade names include Triludan and Seldane), an antihistamine which caused QT interval prolongation, potentially leading to cardiac arrhythmia. It has been described as both second-generation[3] and third-generation antihistamine. The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid, fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite.[8] Fexofenadine was originally synthesized in 1993 by Massachusetts-based biotechnology company Sepracor, which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi-Aventis), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States). AMRI received royalty payments from Aventis that enabled the growth of AMRI. On January 25, 2011, the FDA approved over-the-counter sales of fexofenadine in the United States, with Sanofi-Aventis' version expected to become available on March 4, 2011. I. Originator:Aventis Pharma, Sepracor; Marketer: ViroPharma; Reference patent: JP 1996502022; WO 9321156; II. Main Competitors in U.S: N021963 Yes FEXOFENADINE HYDROCHLORIDE SUSPENSION; ORAL 30MG/5ML ALLEGRA SANOFI AVENTIS US -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076236 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A079043 No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 180MG;240MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076298 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE IMPAX PHARMS III. China Domestic Market I suggest you to look through the SFDA website to get related informations. It is not difficult. IV. The market information is not easy to acquire. I suggest you to purchase IMS data or BMI data. |
3楼2011-03-18 13:36:14
4楼2011-03-18 20:10:17
我主要是为了赚BB5楼2011-03-18 21:35:10
6楼2011-03-29 08:47:19
